Skip to main content
Clinical Trials/CTRI/2022/11/047511
CTRI/2022/11/047511
Not yet recruiting
未知

A prospective, observational study to compare the patient reported outcomes with the use of oral dydrogesterone vs. micronized vaginal progesterone in high risk pregnancies (PERCEPT study) - PERCEPT

Emcure Pharmaceuticals Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: O092- Supervision of pregnancy with other poor reproductive or obstetric history
Sponsor
Emcure Pharmaceuticals Ltd
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Pregnant women with age of \>\= 18 years and who are ready to give informed consent for participation in the study.
  • 2\.Women with clinically diagnosed pregnancy of \<\= 12 weeks of gestation and visiting department of obstetrics and gynecology.
  • 3\.History of more than two miscarriages and/or presenting with vaginal bleeding
  • 4\.Patient suitable for treatment with micronized vaginal progesterone or dydrogesterone therapy based on locally approved prescribing information.

Exclusion Criteria

  • 1\.Pregnant women who have contraindications for use of micronized vaginal progesterone or dydrogesterone.
  • 2\.Any condition that, in the opinion of the investigator, does not justify the patientâ??s inclusion in the study.

Outcomes

Primary Outcomes

Not specified

Similar Trials